Asset profile
Lenalidomide
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Lenalidomide: this drug | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | ||
| Pomalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Cereblon (CRBN) | ||
| Thalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Iberdomide | Phase 3 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Mezigdomide | Phase 3 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Cemsidomide | Phase 2 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| ICP-490 | Phase 1/2 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| TQB3820 | Phase 1 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 |
…and 52 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Pomalidomide · Multiple Myelomavs Thalidomide · Multiple Myelomavs ICP-490 · Multiple Myelomavs Iberdomide · Multiple Myelomavs Mezigdomide · Multiple Myelomavs Cemsidomide · Multiple Myeloma
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(190 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (20)
October 2026 (2)
November 2026 (5)
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2026-11 · NCT03980171 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT06505369 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT06517017 · CT.gov ↗
What to watch
Phase 2Diffuse Large B Cell LymphomaNot yet recruiting
Est. primary completion 2026-11 · NCT06669143 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-11-19 · NCT04174196 · CT.gov ↗
What to watch
December 2026 (13)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2026-12 · NCT01562405 · CT.gov ↗
What to watch
Phase 1NeuroblastomaActive not recruiting
Est. primary completion 2026-12 · NCT02573896 · CT.gov ↗
What to watch
Phase 2Myeloma, MultipleActive not recruiting
Est. primary completion 2026-12 · NCT04009109 · CT.gov ↗
What to watch
Phase 1/2Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt LymphomaRecruiting
Est. primary completion 2026-12-01 · NCT03223610 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2026-12-01 · NCT06549335 · CT.gov ↗
What to watch
Phase 1/2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2026-12-23 · NCT05950165 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-28 · NCT03729804 · CT.gov ↗
What to watch
Early phase / not applicableOral UlcerRecruiting
Est. primary completion 2026-12-30 · NCT05449548 · CT.gov ↗
What to watch
Phase 3Plasma Cell MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT01863550 · CT.gov ↗
What to watch
Phase 1/2CNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT05351593 · CT.gov ↗
What to watch
Phase 2Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements …Recruiting
Est. primary completion 2026-12-31 · NCT05890352 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT06504199 · CT.gov ↗
What to watch
Early phase / not applicableMultiple MyelomaRecruiting
Est. primary completion 2026-12-31 · NCT06697483 · CT.gov ↗
What to watch
2027 (65)
January 2027 (4)
Phase 1Hematological Malignancy, Solid TumorRecruiting
Est. primary completion 2027-01 · NCT05828459 · CT.gov ↗
What to watch
Phase 2Large B-cell LymphomaRecruiting
Est. primary completion 2027-01 · NCT06760156 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaActive not recruiting
Est. primary completion 2027-01-03 · NCT03829371 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-01-16 · NCT04978584 · CT.gov ↗
What to watch
February 2027 (6)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-02 · NCT03070327 · CT.gov ↗
What to watch
Phase 2Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-02 · NCT05583071 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-01 · NCT04268498 · CT.gov ↗
What to watch
Phase 3Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular LymphomaActive not recruiting
Est. primary completion 2027-02-13 · NCT04224493 · CT.gov ↗
What to watch
Phase 2Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder …Recruiting
Est. primary completion 2027-02-18 · NCT06723457 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-26 · NCT04133636 · CT.gov ↗
What to watch
March 2027 (2)
April 2027 (8)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT05558319 · CT.gov ↗
What to watch
Phase 1Primary Diffuse Large B-Cell Lymphoma of the Central Nervous SystemActive not recruiting
Est. primary completion 2027-04-01 · NCT04609046 · CT.gov ↗
What to watch
Phase 2Central Nervous System LymphomaRecruiting
Est. primary completion 2027-04-01 · NCT05260619 · CT.gov ↗
What to watch
Phase 3Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-04-05 · NCT03319667 · CT.gov ↗
What to watch
Phase 2B-cell Non-Hodgkin's LymphomaActive not recruiting
Est. primary completion 2027-04-06 · NCT07081022 · CT.gov ↗
What to watch
Phase 2Rosai-Dorfman DiseaseRecruiting
Est. primary completion 2027-04-12 · NCT07187167 · CT.gov ↗
What to watch
Phase 2Hematopoietic Cell Transplantation Recipient, Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-04-30 · NCT02420860 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-05-31 · NCT06087653 · CT.gov ↗
What to watch
June 2027 (5)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06 · NCT01297764 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06 · NCT05572229 · CT.gov ↗
What to watch
Phase 1/2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-06-24 · NCT03523975 · CT.gov ↗
What to watch
Phase 1Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 InfectionRecruiting
Est. primary completion 2027-06-30 · NCT04301076 · CT.gov ↗
What to watch
Phase 1Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma …Recruiting
Est. primary completion 2027-06-30 · NCT06015880 · CT.gov ↗
What to watch
July 2027 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-07 · NCT03556332 · CT.gov ↗
What to watch
Phase 2Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-07-29 · NCT04876248 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-07-31 · NCT07261163 · CT.gov ↗
What to watch
August 2027 (8)
Phase 2Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-08 · NCT02538198 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-08 · NCT04497961 · CT.gov ↗
What to watch
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2027-08 · NCT05665140 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaActive not recruiting
Est. primary completion 2027-08-10 · NCT06112847 · CT.gov ↗
What to watch
Phase 1Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2027-08-10 · NCT07697339 · CT.gov ↗
What to watch
Phase 2Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHLRecruiting
Est. primary completion 2027-08-19 · NCT05615636 · CT.gov ↗
What to watch
Phase 2Follicular Lymphoma, Marginal Zone Lymphoma, B-cell LymphomaRecruiting
Est. primary completion 2027-08-31 · NCT04792502 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, Follicular LymphomaRecruiting
Est. primary completion 2027-08-31 · NCT06151080 · CT.gov ↗
What to watch
September 2027 (8)
Phase 1/2Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma …Active not recruiting
Est. primary completion 2027-09 · NCT04542824 · CT.gov ↗
What to watch
Phase 3Marginal Zone LymphomaRecruiting
Est. primary completion 2027-09 · NCT06006117 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-09-01 · NCT04096066 · CT.gov ↗
What to watch
Phase 1/2EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor, Tenofovir, Chidamide, LenalidomideNot yet recruiting
Est. primary completion 2027-09-01 · NCT07133763 · CT.gov ↗
What to watch
Phase 1/2Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor, Tenofovir, Chidamide, LenalidomideNot yet recruiting
Est. primary completion 2027-09-01 · NCT07133776 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-09-08 · NCT04635189 · CT.gov ↗
What to watch
Phase 1/2Diffuse Large B-Cell Lymphoma, Follicular LymphomaActive not recruiting
Est. primary completion 2027-09-30 · NCT04663347 · CT.gov ↗
What to watch
Phase 1/2LymphomaActive not recruiting
Est. primary completion 2027-09-30 · NCT05683171 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT03004287 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2027-10-09 · NCT07789522 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2027-10-09 · NCT07828522 · CT.gov ↗
What to watch
November 2027 (4)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-11 · NCT02659293 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaRecruiting
Est. primary completion 2027-11-30 · NCT06409702 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-11-30 · NCT07210047 · CT.gov ↗
What to watch
December 2027 (13)
Phase 1/2Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome …Active not recruiting
Est. primary completion 2027-12 · NCT04623541 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT04891809 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT06461988 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT07297329 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12-20 · NCT04775550 · CT.gov ↗
What to watch
Phase 2MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL)Recruiting
Est. primary completion 2027-12-30 · NCT07460362 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12-31 · NCT03376672 · CT.gov ↗
What to watch
Phase 3Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT04566328 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05091372 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05776979 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT06441097 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-cell Lymphoma, Relapsed and RefractoryRecruiting
Est. primary completion 2027-12-31 · NCT06651853 · CT.gov ↗
What to watch
Phase 2Relapsed/Refractory Follicular LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT07418190 · CT.gov ↗
What to watch
2028 (43)
January 2028 (3)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2028-01-01 · NCT06744894 · CT.gov ↗
What to watch
Phase 2Marginal Zone Lymphoma(MZL)Recruiting
Est. primary completion 2028-01-01 · NCT07448324 · CT.gov ↗
What to watch
Phase 1Mantle Cell Lymphoma, MCLActive not recruiting
Est. primary completion 2028-01-08 · NCT06192888 · CT.gov ↗
What to watch
March 2028 (6)
Phase 3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2028-03 · NCT06508658 · CT.gov ↗
What to watch
Phase 2Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma …Active not recruiting
Est. primary completion 2028-03-01 · NCT04404088 · CT.gov ↗
What to watch
Phase 1/2Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma …Active not recruiting
Est. primary completion 2028-03-21 · NCT05025800 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07045909 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07341867 · CT.gov ↗
What to watch
April 2028 (4)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2028-04 · NCT05243797 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-04-26 · NCT06353022 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2028-04-28 · NCT07299149 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-04-30 · NCT06803693 · CT.gov ↗
What to watch
May 2028 (3)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-05 · NCT05846880 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-05 · NCT07485647 · CT.gov ↗
What to watch
Phase 3Follicular Lymphoma (FL)Recruiting
Est. primary completion 2028-05 · NCT07562022 · CT.gov ↗
What to watch
June 2028 (6)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2028-06 · NCT03617731 · CT.gov ↗
What to watch
Phase 1/2HIV (Human Immunodeficiency Virus), HIV -1 InfectionNot yet recruiting
Est. primary completion 2028-06 · NCT07384624 · CT.gov ↗
What to watch
Phase 2Malignant Plasma Cell NeoplasmsNot yet recruiting
Est. primary completion 2028-06 · NCT07560449 · CT.gov ↗
What to watch
Phase 2Marginal Zone Lymphoma(MZL)Recruiting
Est. primary completion 2028-06-01 · NCT07208981 · CT.gov ↗
What to watch
Phase 2Leukemia, LymphomaActive not recruiting
Est. primary completion 2028-06-30 · NCT01446133 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2028-06-30 · NCT07639138 · CT.gov ↗
What to watch
July 2028 (5)
Phase 4Multiple MyelomaNot yet recruiting
Est. primary completion 2028-07 · NCT07334535 · CT.gov ↗
What to watch
Phase 3Relapsed/Refractory Follicular LymphomaNot yet recruiting
Est. primary completion 2028-07 · NCT07355283 · CT.gov ↗
What to watch
Phase 2Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL) …Not yet recruiting
Est. primary completion 2028-07 · NCT07814001 · CT.gov ↗
What to watch
Phase 2/3IgG4 Related DiseaseRecruiting
Est. primary completion 2028-07-20 · NCT07068165 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2028-07-31 · NCT05583617 · CT.gov ↗
What to watch
August 2028 (1)
Phase 3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-08-10 · NCT06522555 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma …Recruiting
Est. primary completion 2028-09-01 · NCT06649812 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-09-15 · NCT05695508 · CT.gov ↗
What to watch
October 2028 (2)
November 2028 (3)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2028-11 · NCT06284122 · CT.gov ↗
What to watch
Phase 2Primary CNS LymphomaRecruiting
Est. primary completion 2028-11-02 · NCT04627753 · CT.gov ↗
What to watch
Phase 2Plasma Cell MyelomaEnrolling by invitation
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch
December 2028 (7)
Phase 3DLBCL - Diffuse Large B Cell LymphomaRecruiting
Est. primary completion 2028-12-15 · NCT06220032 · CT.gov ↗
What to watch
Phase 2Large B-cell Lymphoma, TP53Recruiting
Est. primary completion 2028-12-30 · NCT07240194 · CT.gov ↗
What to watch
Phase 2Marginal Zone Lymphoma(MZL)Recruiting
Est. primary completion 2028-12-31 · NCT06793189 · CT.gov ↗
What to watch
Phase 2Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPNRecruiting
Est. primary completion 2028-12-31 · NCT07165769 · CT.gov ↗
What to watch
Phase 2Large B-Cell Lymphoma (LBCL)Recruiting
Est. primary completion 2028-12-31 · NCT07514169 · CT.gov ↗
What to watch
Phase 2Relapsed/Refractory Diffuse Large B Cell LymphomaActive not recruiting
Est. primary completion 2028-12-31 · NCT07621406 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07709884 · CT.gov ↗
What to watch
2029 (22)
January 2029 (4)
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2029-01 · NCT06665217 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2029-01-02 · NCT06768489 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗
What to watch
February 2029 (2)
April 2029 (2)
May 2029 (3)
Phase 1/2Follicular Lymphoma, Marginal Zone LymphomaRecruiting
Est. primary completion 2029-05-30 · NCT04669171 · CT.gov ↗
What to watch
Phase 2Relapsed Follicular Lymphoma, Refractory Follicular LymphomaRecruiting
Est. primary completion 2029-05-31 · NCT05848765 · CT.gov ↗
What to watch
Phase 2Large B-Cell Lymphoma (LBCL)Not yet recruiting
Est. primary completion 2029-05-31 · NCT07594899 · CT.gov ↗
What to watch
June 2029 (2)
July 2029 (1)
Phase 2Follicular Lymphoma, Marginal Zone LymphomaRecruiting
Est. primary completion 2029-07-08 · NCT06792825 · CT.gov ↗
What to watch
August 2029 (2)
December 2029 (6)
Phase 3Follicular Lymphoma (FL)Active not recruiting
Est. primary completion 2029-12 · NCT05409066 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-cell LymphomaRecruiting
Est. primary completion 2029-12 · NCT06664411 · CT.gov ↗
What to watch
Phase 2Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell LymphomaRecruiting
Est. primary completion 2029-12-30 · NCT05910801 · CT.gov ↗
What to watch
Phase 3Smoldering Plasma Cell MyelomaRecruiting
Est. primary completion 2029-12-31 · NCT03937635 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-12-31 · NCT06207799 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07585747 · CT.gov ↗
What to watch
2030 (13)
April 2030 (2)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-04-01 · NCT07029776 · CT.gov ↗
What to watch
Phase 1/2Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides …Recruiting
Est. primary completion 2030-04-14 · NCT03011814 · CT.gov ↗
What to watch
July 2030 (2)
September 2030 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗
What to watch
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2030-09-06 · NCT04246086 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-09-30 · NCT06997081 · CT.gov ↗
What to watch
October 2030 (2)
November 2030 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-11-30 · NCT06931704 · CT.gov ↗
What to watch
December 2030 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-12 · NCT05344833 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-12-01 · NCT07247097 · CT.gov ↗
What to watch
Phase 3Immunoglobulin G4-Related DiseaseNot yet recruiting
Est. primary completion 2030-12-31 · NCT07719543 · CT.gov ↗
What to watch
2031 (10)
January 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-01 · NCT06187441 · CT.gov ↗
What to watch
February 2031 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2031-02-14 · NCT07671287 · CT.gov ↗
What to watch
April 2031 (4)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-04-28 · NCT06679101 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-04-30 · NCT05552222 · CT.gov ↗
What to watch
Phase 3Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)Recruiting
Est. primary completion 2031-04-30 · NCT06149286 · CT.gov ↗
What to watch
Early phase / not applicableMarginal Zone Lymphoma(MZL)Not yet recruiting
Est. primary completion 2031-04-30 · NCT07299331 · CT.gov ↗
What to watch
May 2031 (2)
November 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-11 · NCT07285239 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Large B Cell LymphomaRecruiting
Est. primary completion 2031-12-27 · NCT07126236 · CT.gov ↗
What to watch
2032 (6)
January 2032 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2032-01-31 · NCT06182774 · CT.gov ↗
What to watch
September 2032 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2032-09 · NCT04071457 · CT.gov ↗
What to watch
November 2032 (3)
Phase 2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2032-11 · NCT05283720 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2032-11 · NCT06974786 · CT.gov ↗
What to watch
Phase 2Plasma Cell LeukemiaRecruiting
Est. primary completion 2032-11-06 · NCT07605416 · CT.gov ↗
What to watch
December 2032 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2032-12-02 · NCT06910124 · CT.gov ↗
What to watch
2033 (4)
May 2033 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2033-05-28 · NCT05145400 · CT.gov ↗
What to watch
June 2033 (2)
September 2033 (1)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2033-09 · NCT05259839 · CT.gov ↗
What to watch
2035 (2)
February 2035 (1)
Phase 1/2Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, PrimaryActive not recruiting
Est. primary completion 2035-02-02 · NCT04446962 · CT.gov ↗
What to watch
December 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch
2036 (3)
May 2036 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2036-05 · NCT06918002 · CT.gov ↗
What to watch
September 2036 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2036-09-30 · NCT07600151 · CT.gov ↗
What to watch
December 2036 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2036-12 · NCT06932562 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
Phase 3Follicular Lymphoma (FL)Active not recruiting
Est. primary completion 2037-11 · NCT06191744 · CT.gov ↗
What to watch
2040 (1)
September 2040 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2040-09 · NCT07095452 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.